Ipol Injection, Suspension
NDC Package 49281-860-10
Package Information
Ipol (poliovirus type 1 antigen (formaldehyde inactivated), poliovirus type 2 antigen (formaldehyde inactivated), and poliovirus type 3 antigen (formaldehyde inactivated)) injection is iPOL vaccine is indicated for active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Types 1, 2, and 3. This formulation utilizes a injection, suspension delivery system. Marketed by Sanofi Vaccines Us Inc., this product is identified by NDC 49281-860 and is authorized under FDA application BLA103930.
Identification & Billing
- RxCUI: 763103 - poliovirus vaccine, inactivated (IPV) Injectable Suspension
- RxCUI: 763103 - poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Suspension
- RxCUI: 763103 - poliovirus vaccine inactivated, type 1 (Mahoney) 40 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 8 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 32 UNT/ML per 0.5 ML Injectable Suspension
- RxCUI: 763106 - IPOL vaccine Injectable Suspension
- RxCUI: 763106 - poliovirus vaccine inactivated, type 1 (Mahoney) 80 UNT/ML / poliovirus vaccine inactivated, type 2 (MEF-1) 16 UNT/ML / poliovirus vaccine inactivated, type 3 (Saukett) 64 UNT/ML Injectable Suspension [Ipol]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 49281 - Sanofi Vaccines Us Inc.
- 49281-860 - Ipol
- 49281-860-10 - 1 VIAL, MULTI-DOSE in 1 PACKAGE / 5 mL in 1 VIAL, MULTI-DOSE (49281-860-78)
- 49281-860 - Ipol
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 49281-860-10 identifies a specific commercial package of 1 vial, multi-dose in 1 package / 5 ml in 1 vial, multi-dose (49281-860-78) of Ipol, a vaccine label labeled by Sanofi Vaccines Us Inc.. This product is billed per "ML" milliliter and contains an estimated amount of 5 billable units per package. This injection, suspension is formulated for intramuscular use and contains poliovirus type 1 antigen (formaldehyde inactivated); poliovirus type 2 antigen (formaldehyde inactivated); poliovirus type 3 antigen (formaldehyde inactivated) as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Sanofi Vaccines Us Inc. on December 21, 1990. The current certification is valid through December 31, 2027.
How is this Sanofi Vaccines Us Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 49281086010. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. There are 5 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.